Department of Surgery, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea.
Ann Surg Oncol. 2012 Feb;19(2):494-501. doi: 10.1245/s10434-011-1987-6. Epub 2011 Aug 12.
Curative resection, including gastrectomy, extensive lymph node dissection, and combined resection of invaded organs, is the mainstay of treatment for T4b gastric cancers. We sought to investigate the clinicopathologic features, surgical outcomes, and prognostic factors of curatively resected pathologic T4b gastric cancer with a focus on organs invaded.
Data of 243 pT4b gastric cancer patients who underwent curative resection at Korea Cancer Center Hospital from 1991 to 2005 were retrospectively subjected to univariate and multivariate analyses.
Overall 5-year survival rate and median survival time were 36.8% and 26 months, respectively. Five-year survival rates were 23.3% in the pancreatic invasion group (n = 67) and 42.1% in the nonpancreatic invasion group (n = 176) (P = 0.002). Regarding operative methods used for pancreatectomy in pancreatic invasion group, 5-year survival rates were 0% in the pancreaticoduodenectomy group (n = 9) and 27.4% in the other pancreatectomies group (n = 58) (P = 0.013). Multivariate analysis revealed that advanced lymph node stages (hazard ratio [HR] 1.637 for N0 vs. N1, HR 2.177 for N0 vs. N2, HR 3.241 for N0 vs. N3a, and HR 4.000 for N0 vs. N3b), encircling type of tumor (HR 1.804), and pancreatic invasion (HR 1.463) were independently unfavorable prognostic factors.
In pT4b gastric cancer, pancreatic invasion was found to portend the least favorable prognosis, especially in cases requiring pancreaticoduodenectomy. However, prognoses were more favorable after curative resection in patients without advanced lymph node stages (N2, N3a, and N3b), an encircling type of gastric tumor, or pancreatic invasion. We propose a novel therapeutic strategy for patients with T4b gastric cancer.
包括胃切除术、广泛淋巴结清扫术以及联合受侵器官切除术在内的根治性切除术是 T4b 胃癌的主要治疗方法。我们旨在探讨可根治性切除的病理性 T4b 胃癌(重点关注受侵器官)的临床病理特征、手术结果和预后因素。
回顾性分析了 1991 年至 2005 年在韩国癌症中心医院接受根治性切除术的 243 例 pT4b 胃癌患者的数据,并进行了单因素和多因素分析。
总体 5 年生存率和中位生存时间分别为 36.8%和 26 个月。胰腺受侵组(n=67)和非胰腺受侵组(n=176)的 5 年生存率分别为 23.3%和 42.1%(P=0.002)。在胰腺受侵组中,行胰腺切除术的患者中,胰十二指肠切除术组(n=9)的 5 年生存率为 0%,其他胰腺切除术组(n=58)的 5 年生存率为 27.4%(P=0.013)。多因素分析显示,淋巴结分期较晚(N0 与 N1 相比,HR=1.637;N0 与 N2 相比,HR=2.177;N0 与 N3a 相比,HR=3.241;N0 与 N3b 相比,HR=4.000)、肿瘤环绕型(HR=1.804)和胰腺受侵(HR=1.463)是独立的预后不良因素。
在 pT4b 胃癌中,胰腺受侵预示着最差的预后,尤其是在需要行胰十二指肠切除术的情况下。然而,对于无淋巴结转移(N2、N3a 和 N3b)、环绕型胃肿瘤或无胰腺受侵的患者,根治性切除后的预后更为有利。我们提出了一种新的 T4b 胃癌治疗策略。